ClinicalTrials.gg
CompletedNCT04186819Updated Feb 26, 2025Results posted

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

A Phase 3 interventional study of rhPSMA-7.3 (18F) Injection and Positron Emission Tomography scan in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 34 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.

Enrollment
2nd of 15
356 · median 70
Started
2020
with 1 other
Phase 3
4 of 15
1 open now
Registered
2nd of 15
by date
Lead sponsor
4 of 15
Blue Earth Diagnostics

Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About flotufolastat F 18

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

Read the detailed description

Main objective is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central blinded image evaluation [BIE]) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during radical prostatectomy (RP) and pelvic lymph node dissection (PLND). At least one positive pelvic LN on PET (N1) and one positive lymph node (LN) as determined by histopathology (pN1) on the same side of the pelvis (left or right) will be deemed a True Positive (TP) at the patient level.

03

Conditions studied

  • Prostate Cancer

Keywords

  • Primary Prostate Cancer
  • Diagnostic
  • Prostate Specific Membrane Antigen (PSMA)
  • Positron Emission Tomography (PET) Scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is male and aged >18 years old.
  2. confirmed adenocarcinoma of the prostate.
  3. Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).

Exclusion criteria

Exclusion Criteria:

  1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer \<24 hours prior to the PET scan.
  2. Patients currently receiving, or with a prior history of, Androgen Deprivation Therapy (ADT).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Patients

    Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

    Drug: rhPSMA-7.3 (18F) Injection · Diagnostic Test: Positron Emission Tomography scan

Interventions

  • Radioligand for PET CT scanning

    Also known as: No other interventions

  • Diagnostic testPositron Emission Tomography scan

    imaging test with radioligand

    Also known as: PET scan

06

What researchers measure

Primary outcomes

  1. Specificity

    The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  2. Sensitivity

    The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

Secondary outcomes

  1. Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1)

    This was a key secondary endpoint in this study and included patients in the EEP with rhPSMA-7.3 (18F) imaging.

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET. followed by treatment within 60 days post IMP administration

  2. Percentage of Patients With Negative Conventional Imaging for M1 Disease in Whom rhPSMA-7.3 (18F) PET Detected at Least One Verified M1 Metastasis, as Determined by Central BIE (Objective 2)

    Patients counted in this variable were a subset of those in Point 1 above, where both the numerator and denominator were only counting patients with negative conventional imaging (according to investigator assessment) for M1 disease.

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  3. Patient-level PPV of rhPSMA-7.3 (18F) PET BIE for N1 and M1 Lesions Compared to Histopathology or Confirmatory Imaging (M1 Lesions Only) (Objective 3)

    This analysis included patients with rhPSMA-7.3 (18F) imaging and either N1 or M1 lesions detected, where PPV=TP/(TP+FP).

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  4. PPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FP Patient is Defined as Having at Least One FP Region (Right or Left Pelvis), Regardless of Any Coexisting TP Findings (Objective 4)

    This analysis included patients in the EAP where rhPSMA-7.3 (18F) imaging detected PLN metastasis. Regions where rhPSMA7.3 (18F) imaging detected no LN metastasis were not included (by definition of PPV), hence only TP and FP regions were considered. TPs were all patients with a surgical pathology confirmed positive region and without a FP region. FP patients were those patients with any rhPSMA7.3 (18F) PETpositive region with negative or no surgical pathology.

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  5. NPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FN Patient is Defined as Having at Least One FN Region (Right or Left Pelvis), Regardless of Any Coexisting TN Findings (Objective 5)

    This analysis included patients in the EAP with rhPSMA-7.3 (18F) imaging where no LN metastases were detected and LN surgical pathology was available; where NPV=TN/(TN+FN).

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  6. The Percentage of Patients Being Upstaged to N1 or M1 Disease. (Objective 6a)

    TP \[confirmed by SoT\] central BIE PET finding and negative conventional imaging finding from the local reading

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  7. The Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b)

    Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration

  8. Kappa Statistic for the Agreement Between and Within Blinded Independent Readers on the Interpretation of rhPSMA-7.3 (18F) Scans (Objective 7)

    Pairwise agreement between any 2 of the 3 readers (Kappa statistic could not be calculated for 2 of the pairwise agreements), and within readers between the initial read and re-read (Kappa statistics could not be calculated for 2 of the within-reader agreements)

    Time frame: PET/CT scans on Day 1

07

Results

Posted Feb 26, 2025

Participant flow

This study was from 02 Mar 20 (first patient, screening visit) and 18 Feb 22 (database lock), with the last patient, last visit on 21 Jun 21. It was conducted at 34 activated study sites (31 recruited) in 4 countries. Of the 372 patients screened, 356 patients met all the study eligibility criteria. 16 patients were screen failures so not included

Participant flow — Overall Study
MilestonePatients
Started356
Completed336
Not completed20
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Opted for ebrt1
Withdrew: Opted sbrt1
Withdrew: Patient decided to have focal ablation and not surgery2
Withdrew: Physician decision1
Withdrew: Rp delayed1
Withdrew: Sponsor decision: outdated fu timeline1
Withdrew: Subject declined for financial reasons1
Withdrew: The subject declined any biopsy or surgery due to covid-19 pandemic1
Withdrew: The subject declined for any biopsy or other imaging2
Withdrew: The subject opted for other treatment option2
Withdrew: The subject opted for other treatment options1
Withdrew: Withdrawal by subject3
Withdrew: Reason not specified1

Outcome measures

PrimarySpecificity

The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
Specificity
percentageEfficacy Analysis Population
Central Reader 192.9 (88.8 to 95.9)
Central Reader 293.8 (89.8 to 96.6)
Central Reader 396.9 (93.7 to 98.7)
PrimarySensitivity

The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
Sensitivity
percentageEfficacy Analysis Population
Central Reader 130 (19.6 to 42.1)
Central Reader 227.1 (17.2 to 39.1)
Central Reader 322.9 (13.7 to 34.4)
SecondaryVerified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1)

This was a key secondary endpoint in this study and included patients in the EEP with rhPSMA-7.3 (18F) imaging.

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET. followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1)
percentageExtended Efficacy Population (EEP)
Central Reader 19.9 (7.0 to 13.6)
Central Reader 214.2 (10.7 to 18.3)
Central Reader 310.2 (7.3 to 13.9)
SecondaryPercentage of Patients With Negative Conventional Imaging for M1 Disease in Whom rhPSMA-7.3 (18F) PET Detected at Least One Verified M1 Metastasis, as Determined by Central BIE (Objective 2)

Patients counted in this variable were a subset of those in Point 1 above, where both the numerator and denominator were only counting patients with negative conventional imaging (according to investigator assessment) for M1 disease.

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
Percentage of Patients With Negative Conventional Imaging for M1 Disease in Whom rhPSMA-7.3 (18F) PET Detected at Least One Verified M1 Metastasis, as Determined by Central BIE (Objective 2)
percentageExtended Efficacy Population (EEP)
Central Reader 18.8 (5.9 to 12.3)
Central Reader 213.0 (9.6 to 17.1)
Central Reader 38.5 (5.7 to 12.0)
SecondaryPatient-level PPV of rhPSMA-7.3 (18F) PET BIE for N1 and M1 Lesions Compared to Histopathology or Confirmatory Imaging (M1 Lesions Only) (Objective 3)

This analysis included patients with rhPSMA-7.3 (18F) imaging and either N1 or M1 lesions detected, where PPV=TP/(TP+FP).

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
Patient-level PPV of rhPSMA-7.3 (18F) PET BIE for N1 and M1 Lesions Compared to Histopathology or Confirmatory Imaging (M1 Lesions Only) (Objective 3)
percentageEfficacy Analysis Population (EAP)Extended Efficacy Population (EEP)
Central Reader 156.8 (39.5 to 72.9)62.5 (48.5 to 75.1)
Central Reader 257.6 (39.2 to 74.5)51.0 (40.7 to 61.3)
Central Reader 369.6 (47.1 to 86.8)57.1 (44.0 to 69.5)
SecondaryPPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FP Patient is Defined as Having at Least One FP Region (Right or Left Pelvis), Regardless of Any Coexisting TP Findings (Objective 4)

This analysis included patients in the EAP where rhPSMA-7.3 (18F) imaging detected PLN metastasis. Regions where rhPSMA7.3 (18F) imaging detected no LN metastasis were not included (by definition of PPV), hence only TP and FP regions were considered. TPs were all patients with a surgical pathology confirmed positive region and without a FP region. FP patients were those patients with any rhPSMA7.3 (18F) PETpositive region with negative or no surgical pathology.

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
PPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FP Patient is Defined as Having at Least One FP Region (Right or Left Pelvis), Regardless of Any Coexisting TP Findings (Objective 4)
percentageEfficacy Analysis Population (EAP)
Central Reader 148.6 (31.9 to 65.6)
Central Reader 254.5 (36.4 to 71.9)
Central Reader 365.2 (42.7 to 83.6)
SecondaryNPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FN Patient is Defined as Having at Least One FN Region (Right or Left Pelvis), Regardless of Any Coexisting TN Findings (Objective 5)

This analysis included patients in the EAP with rhPSMA-7.3 (18F) imaging where no LN metastases were detected and LN surgical pathology was available; where NPV=TN/(TN+FN).

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
NPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FN Patient is Defined as Having at Least One FN Region (Right or Left Pelvis), Regardless of Any Coexisting TN Findings (Objective 5)
percentageEfficacy Analysis Population (EAP)
Central Reader 181.3 (76.3 to 85.7)
Central Reader 280.8 (75.8 to 85.2)
Central Reader 379.9 (74.8 to 84.4)
SecondaryThe Percentage of Patients Being Upstaged to N1 or M1 Disease. (Objective 6a)

TP \[confirmed by SoT\] central BIE PET finding and negative conventional imaging finding from the local reading

Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
The Percentage of Patients Being Upstaged to N1 or M1 Disease. (Objective 6a)
percentageUpstaged to N1Upstaged to M1
Central Reader 15.18.2
Central Reader 24.312.2
Central Reader 33.78.0
SecondaryThe Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b)
Time frame:
Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Reported as:
Number · percentage
The Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b)
percentageExtended Efficacy Population (EEP)
The Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b)2.6
SecondaryKappa Statistic for the Agreement Between and Within Blinded Independent Readers on the Interpretation of rhPSMA-7.3 (18F) Scans (Objective 7)

Pairwise agreement between any 2 of the 3 readers (Kappa statistic could not be calculated for 2 of the pairwise agreements), and within readers between the initial read and re-read (Kappa statistics could not be calculated for 2 of the within-reader agreements)

Time frame:
PET/CT scans on Day 1
Reported as:
Number · percentage
Kappa Statistic for the Agreement Between and Within Blinded Independent Readers on the Interpretation of rhPSMA-7.3 (18F) Scans (Objective 7)
percentageExtended Efficacy Population (EEP)
Agreement between reader 1 and reader 297.7
Agreement between Reader 1 and Reader 395.2
Agreement between Reader 2 and Reader 396.9
Agreement between initial read and re-read in Reader 1100
Agreement between initial read and re-read in Reader 2100
Agreement between initial read and re-read in Reader 395.7

Adverse events

Collected over All AEs were recorded throughout the study from informed consent through study completion, an average of 60 days post-IMP administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Safety Population (FSP)0/356 (0%)0/356 (0%)28/356 (7.9%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventFull Safety Population (FSP)
HeadacheNervous system disorders5/356
Injection site painGeneral disorders3/356
NauseaGastrointestinal disorders3/356
HypertensionVascular disorders2/356
Tracheal deviationInjury, poisoning and procedural complications1/356
Aortic aneurysmVascular disorders1/356
ThrombophlebitisVascular disorders1/356
Atrial fibrillationCardiac disorders1/356
DysgeusiaNervous system disorders1/356
ChillsGeneral disorders1/356

Baseline characteristics

The FAS comprised 356 patients who were scheduled to receive the rhPSMA-7.3 (18F) injection and met the inclusion/exclusion criteria

Age, Continuous
Age, Continuous(years)Single Arm
Mean64.9 ± 6.98
Age, Customized
Age, Customized(participants)Single Arm
< 65 years163
≥ 65 years193
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female0
Male356
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Arm
Hispanic or Latino17
Not Hispanic or Latino311
Unknown or Not Reported28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Single Arm
Black or African American30
White289
Other4
Not Reported33
Region of Enrollment
Region of Enrollment(participants)Single Arm
Netherlands14
United States238
Finland18
Germany86
Total Gleason Score
Total Gleason Score(participants)Single Arm
=7160
=887
=997
=106
≤ 66
TNM (Tumor-Node-Metastasis) Stage T
TNM (Tumor-Node-Metastasis) Stage T(participants)Single Arm
T116
T1a2
T1c127
T258
T2a18
T2b25
T2c33
T320
T3a21
T3b12
T3c1
T42
TX9
Missing12

9 further baseline measures are reported on the registry.

08

Study locations

34 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • University of California Irvine Medical Center (UCIMC)
    Orange, California 92868, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90403, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Austell, Georgia 30342, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Richard L Roudebush VA Medical Center
    Indianapolis, Indiana 46278, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Chesapeake Urology Research Associates
    Towson, Maryland 21204, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan, Ann Arbor
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • The Urologic Institute of Northeastern New York - Community
    Albany, New York 12208, United States
  • Montefiore Hospital
    Bronx, New York 10461, United States
  • Queens Hospital Center (QHC) - Queens Cancer Center
    Jamaica, New York 11432, United States
  • Mount Sinai Faculty Practice Associates
    New York, New York 10029, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Duke University Medical Center
    Durham, North Carolina 27701, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • MidLantic Urology
    Philadelphia, Pennsylvania 19004, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • MD Anderson Hospital
    Houston, Texas 77054, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • University of Virginia - Health Science Center
    Charlottesville, Virginia 22908, United States
  • Virginia Oncology Associates PC
    Norfolk, Virginia 23502, United States
  • Turku University Hospital
    Turku, FI-20520, Finland
  • Klinik und Poliklinik fur Urologie
    Hamburg, 20246, Germany
  • TU München
    Munich, 81675, Germany
  • CWZ
    Nijmegen, 6532, Netherlands
  • Maxima MC
    Veldhoven, 5504 DB, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jun 2021, 15 months.

Results were first posted in Feb 2025, 3 years 8 months after primary completion. A results delay was requested in Mar 2022.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 15 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Dec 5, 2019
StartActual
Mar 2, 2020
Primary completionActual
Jun 21, 2021
CompletionActual
Jun 21, 2021
Results delay requested
Mar 15, 2022
Results first posted
Feb 26, 2025
Last update
Feb 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04186819
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Mar 2, 2020
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021
Results posted
Feb 26, 2025
Last update
Feb 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flotufolastat F 18

Start the discussion